Biogen Inc. (NASDAQ: BIIB) reported fourth quarter 2021 earnings results today. Total revenue decreased 4% year-over-year to $2.73 billion. GAAP net income attributable to Biogen Inc. was $368 million, or $2.50 per share, compared to $358 million, or $2.32 per share, last year. Adjusted net income was $500 million, or $3.39 per share. For the […]
Biogen Inc. (NASDAQ: BIIB) reported fourth quarter 2021 earnings results today. Total revenue decreased 4% year-over-year to $2.73 billion. GAAP net income attributable to Biogen Inc. was $368 million, or $2.50 per share, compared to $358 million, or $2.32 per share, last year. Adjusted net income was $500 million, or $3.39 per share. For the […]
Biogen Inc. (NASDAQ: BIIB) reported fourth quarter 2021 earnings results today.
Total revenue decreased 4% year-over-year to $2.73 billion.
GAAP net income attributable to Biogen Inc. was $368 million, or $2.50 per share, compared to $358 million, or $2.32 per share, last year. Adjusted net income was $500 million, or $3.39 per share.
For the full year of 2022, Biogen expects revenue to range between $9.7-10 billion and adjusted EPS to range between $14.25-16.00.
